Last updated on February 2017

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma


Brief description of study

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Detailed Study Description

The purpose of this study is to evaluate the safety/tolerability and efficacy of INCB039110 in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Clinical Study Identifier: TX147673

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )